company background image
ROVI

Laboratorios Farmaceuticos RoviBME:ROVI Stock Report

Market Cap

€3.4b

7D

6.6%

1Y

92.9%

Updated

24 Oct, 2021

Data

Company Financials +
ROVI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance6/6
Financial Health6/6
Dividends0/6

ROVI Overview

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Laboratorios Farmaceuticos Rovi
Historical stock prices
Current Share Price€60.00
52 Week High€30.20
52 Week Low€68.80
Beta0.62
1 Month Change6.01%
3 Month Change-1.96%
1 Year Change92.93%
3 Year Change270.37%
5 Year Change385.83%
Change since IPO500.00%

Recent News & Updates

Sep 24
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

ROVIES PharmaceuticalsES Market
7D6.6%1.4%-0.6%
1Y92.9%18.9%23.8%

Return vs Industry: ROVI exceeded the Spanish Pharmaceuticals industry which returned 18.9% over the past year.

Return vs Market: ROVI exceeded the Spanish Market which returned 23.8% over the past year.

Price Volatility

Is ROVI's price volatile compared to industry and market?
ROVI volatility
ROVI Beta0.62
Industry Beta0.44
Market Beta1

Stable Share Price: ROVI is more volatile than 90% of Spanish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ROVI's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
19461,499Juan Lopez-Belmonte Encinahttps://www.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.

Laboratorios Farmaceuticos Rovi Fundamentals Summary

How do Laboratorios Farmaceuticos Rovi's earnings and revenue compare to its market cap?
ROVI fundamental statistics
Market Cap€3.36b
Earnings (TTM)€82.49m
Revenue (TTM)€518.88m

40.8x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ROVI income statement (TTM)
Revenue€518.88m
Cost of Revenue€239.72m
Gross Profit€279.16m
Expenses€196.68m
Earnings€82.49m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.47
Gross Margin53.80%
Net Profit Margin15.90%
Debt/Equity Ratio13.8%

How did ROVI perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

26%

Payout Ratio

Valuation

Is Laboratorios Farmaceuticos Rovi undervalued compared to its fair value and its price relative to the market?

1.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ROVI (€60) is trading below our estimate of fair value (€60.82)

Significantly Below Fair Value: ROVI is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ROVI is poor value based on its PE Ratio (40.8x) compared to the European Pharmaceuticals industry average (27.7x).

PE vs Market: ROVI is poor value based on its PE Ratio (40.8x) compared to the Spanish market (23.2x).


Price to Earnings Growth Ratio

PEG Ratio: ROVI is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: ROVI is overvalued based on its PB Ratio (8.3x) compared to the XE Pharmaceuticals industry average (3.4x).


Future Growth

How is Laboratorios Farmaceuticos Rovi forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

18.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROVI's forecast earnings growth (18.5% per year) is above the savings rate (0.9%).

Earnings vs Market: ROVI's earnings (18.5% per year) are forecast to grow faster than the Spanish market (16.8% per year).

High Growth Earnings: ROVI's earnings are forecast to grow, but not significantly.

Revenue vs Market: ROVI's revenue (8.4% per year) is forecast to grow faster than the Spanish market (6.5% per year).

High Growth Revenue: ROVI's revenue (8.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ROVI's Return on Equity is forecast to be high in 3 years time (23.8%)


Past Performance

How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?

30.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ROVI has high quality earnings.

Growing Profit Margin: ROVI's current net profit margins (15.9%) are higher than last year (13.3%).


Past Earnings Growth Analysis

Earnings Trend: ROVI's earnings have grown significantly by 30.4% per year over the past 5 years.

Accelerating Growth: ROVI's earnings growth over the past year (56.5%) exceeds its 5-year average (30.4% per year).

Earnings vs Industry: ROVI earnings growth over the past year (56.5%) exceeded the Pharmaceuticals industry 10.2%.


Return on Equity

High ROE: ROVI's Return on Equity (20.4%) is considered high.


Financial Health

How is Laboratorios Farmaceuticos Rovi's financial position?


Financial Position Analysis

Short Term Liabilities: ROVI's short term assets (€439.3M) exceed its short term liabilities (€167.4M).

Long Term Liabilities: ROVI's short term assets (€439.3M) exceed its long term liabilities (€73.0M).


Debt to Equity History and Analysis

Debt Level: ROVI's debt to equity ratio (13.8%) is considered satisfactory.

Reducing Debt: ROVI's debt to equity ratio has reduced from 22.6% to 13.8% over the past 5 years.

Debt Coverage: ROVI's debt is well covered by operating cash flow (267.7%).

Interest Coverage: ROVI's interest payments on its debt are well covered by EBIT (309.7x coverage).


Balance Sheet


Dividend

What is Laboratorios Farmaceuticos Rovi current dividend yield, its reliability and sustainability?

0.63%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ROVI's dividend (0.64%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (1.5%).

High Dividend: ROVI's dividend (0.64%) is low compared to the top 25% of dividend payers in the Spanish market (5.45%).


Stability and Growth of Payments

Stable Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.

Growing Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: ROVI is not paying a notable dividend for the Spanish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ROVI's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.1yrs

Average management tenure


CEO

Juan Lopez-Belmonte Encina

4.75yrs

Tenure

€561,000

Compensation

Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. He has been with Laboratorios Farmaceuticos ROVI since 1994 and served as its Ge...


CEO Compensation Analysis

Compensation vs Market: Juan's total compensation ($USD652.55K) is below average for companies of similar size in the Spanish market ($USD1.46M).

Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ROVI's management team is seasoned and experienced (12.1 years average tenure).


Board Members

Experienced Board: ROVI's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Laboratorios Farmaceuticos Rovi, S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Laboratorios Farmaceuticos Rovi, S.A.
  • Ticker: ROVI
  • Exchange: BME
  • Founded: 1946
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.364b
  • Shares outstanding: 56.07m
  • Website: https://www.rovi.es

Number of Employees


Location

  • Laboratorios Farmaceuticos Rovi, S.A.
  • Calle José Isbert, 2
  • Pozuelo de Alarcón
  • Madrid
  • Madrid
  • 28223
  • Spain

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 17:55
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.